Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been given an average rating of “Buy” by the ten research firms that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The average 12 month price […]
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has been given an average rating of “Buy” by the ten research firms that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. The average 12 month price […]